Evotec AG shares climbed 3.6% on the session after the company confirmed that the U.S. Food and Drug Administration has accepted a second Investigational New Drug application stemming from its strategic protein degradation collaboration with Bristol Myers Squibb. The submission relates to a molecular glue candidate that is targeted to begin Phase 1 clinical testing in 2027.
Company commentary described the acceptance as evidence of the productivity of the collaboration's molecular glue discovery platform and its potential to address patient populations with unmet medical needs. That clinical milestone was the most direct driver cited for investor interest in the stock on the day.
Alongside the regulatory news, Evotec said it had finished a share repurchase program. The company bought 365,000 shares on Xetra between November 10 and 13. Those repurchased shares are intended to be converted into American Depositary Shares for use in an employee equity program. Management framed the buyback's completion as an indication of confidence in the share price at current levels.
Market-wide strength reinforced the positive tone for Evotec. U.S. indexes traded higher, with the S&P 500 up 1.0% and the Nasdaq rising 1.8%, helping lift sentiment across global risk assets, including European biotechnology stocks. Germany's DAX index also moved into positive territory, providing a constructive backdrop for shares listed in Frankfurt.
These factors coincided with at least one analyst increasing a price target for Evotec, and together they pushed the stock up to a session high of 82.6. That intraday peak remains substantially below the company's 52-week high of 6.73, but it is well above the 52-week low of .406 recorded earlier this year.
Investors therefore reacted to a convergence of events: a regulatory acceptance that advances a program out of preclinical stages, the formal close of a buyback aimed at supporting employee compensation in ADS form, and an analyst reassessment of the company's valuation. Each element contributed to improved market sentiment for the stock during the trading session.
While the FDA acceptance sets a concrete near-term milestone - the planned Phase 1 start in 2027 - the company and its investors will continue to monitor subsequent clinical and market developments as they unfold.
Note on market context: The price moves described occurred amid broader equity gains led by U.S. benchmarks and positive trading in European markets, factors that helped amplify demand for biotechnology and pharma-related equities on the day.